Iteos Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.535
- Today's High:
- $13.03
- Open Price:
- $12.79
- 52W Low:
- $11.34
- 52W High:
- $23
- Prev. Close:
- $12.73
- Volume:
- 151658
Company Statistics
- Market Cap.:
- $439.04 million
- Book Value:
- 17.426
- Revenue TTM:
- $85.99 million
- Operating Margin TTM:
- -74.6%
- Gross Profit TTM:
- $267.63 million
- Profit Margin:
- -33.04%
- Return on Assets TTM:
- -5.28%
- Return on Equity TTM:
- -4.51%
Company Profile
Iteos Therapeutics Inc had its IPO on 2020-07-24 under the ticker symbol ITOS.
The company operates in the Healthcare sector and Biotechnology industry. Iteos Therapeutics Inc has a staff strength of 125 employees.
Stock update
Shares of Iteos Therapeutics Inc opened at $12.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.54 - $13.03, and closed at $12.85.
This is a +0.94% increase from the previous day's closing price.
A total volume of 151,658 shares were traded at the close of the day’s session.
In the last one week, shares of Iteos Therapeutics Inc have increased by +4.73%.
Iteos Therapeutics Inc's Key Ratios
Iteos Therapeutics Inc has a market cap of $439.04 million, indicating a price to book ratio of 1.187 and a price to sales ratio of 1.6815.
In the last 12-months Iteos Therapeutics Inc’s revenue was $85.99 million with a gross profit of $267.63 million and an EBITDA of $-63267000. The EBITDA ratio measures Iteos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Iteos Therapeutics Inc’s operating margin was -74.6% while its return on assets stood at -5.28% with a return of equity of -4.51%.
In Q2, Iteos Therapeutics Inc’s quarterly earnings growth was a negative -88.6% while revenue growth was a negative 91.7%.
Iteos Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 12.5628
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.81 per share while it has a forward price to earnings multiple of 12.5628 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Iteos Therapeutics Inc’s profitability.
Iteos Therapeutics Inc stock is trading at a EV to sales ratio of 0.0111 and a EV to EBITDA ratio of 0.0154. Its price to sales ratio in the trailing 12-months stood at 1.6815.
Iteos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $703.75 million
- Total Liabilities
- $30.02 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $700000
- Dividend Payout Ratio
- 0%
Iteos Therapeutics Inc ended 2024 with $703.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $703.75 million while shareholder equity stood at $623.53 million.
Iteos Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $30.02 million in other current liabilities, 36000.00 in common stock, $187.42 million in retained earnings and $0 in goodwill. Its cash balance stood at $216.21 million and cash and short-term investments were $599.22 million. The company’s total short-term debt was $1,021,000 while long-term debt stood at $0.
Iteos Therapeutics Inc’s total current assets stands at $614.55 million while long-term investments were $78.26 million and short-term investments were $383.01 million. Its net receivables were $3.68 million compared to accounts payable of $5.23 million and inventory worth $0.
In 2024, Iteos Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $700000.
Comparatively, Iteos Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.85
- 52-Week High
- $23
- 52-Week Low
- $11.34
- Analyst Target Price
- $39.75
Iteos Therapeutics Inc stock is currently trading at $12.85 per share. It touched a 52-week high of $23 and a 52-week low of $23. Analysts tracking the stock have a 12-month average target price of $39.75.
Its 50-day moving average was $13.04 and 200-day moving average was $15.82 The short ratio stood at 8.16 indicating a short percent outstanding of 0%.
Around 37.6% of the company’s stock are held by insiders while 10440.8% are held by institutions.
Frequently Asked Questions About Iteos Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc”R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.